FCP Biotech Holding

FCP Biotech Holding is an Austrian investment firm and holding company that serves as a strategic vehicle for biotechnology investments, most notably Apeiron Biologics and its research spin-off, invIOs. The company is recognized for its role in the development and management of high-value life science assets, including the pediatric neuroblastoma treatment dinutuximab beta (Qarziba). Through its clinical-stage subsidiaries, FCP Biotech Holding focuses on the development of novel immuno-oncology therapies targeting intracellular checkpoints like Cbl-b. Based in Vienna, the company provides capital and management expertise to advance innovative modalities such as small molecules and cell-based therapies. It remains a significant player in the European biotech ecosystem by managing intellectual property and royalty streams from successful drug commercialization.